Danish pharmaceutical company focused on brain diseases: depression, migraine, Parkinson's and other CNS disorders.
Danish pharmaceutical company focused on brain diseases: depression, migraine, Parkinson's and other CNS disorders.
Earns from selling its own brain-disease drugs in Europe, the US and elsewhere through its own sales forces, and from sharing profits on drugs co-developed with Otsuka, such as Rexulti. A few older products face generic competition when patents expire, so it keeps buying or licensing newer ones, including its 2024 purchase of Longboard. The Lundbeck Foundation, a Danish charity, controls it.
Moat: narrow (IP / patents, process know-how). Deep, focused CNS drug-development expertise but faces patent expiries on key products.
Headquarters: Valby, Denmark · Founded: 1915 · Employees: 5,214
Size H. Lundbeck A/S (HLUN-A.CO) is a Denmark Health Care company (Pharmaceuticals: Major) with a market value of $9.16B, the 15th largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 60.40 on 18 Nov 2026.
Performance Over six months the shares gained 69.2%, against +19.2% for the median peer and +6.3% for the Denmark market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 9.1% over the last twelve months (peer median +15.3%); the operating margin is 25.5% (peer median 15.4%).
Valuation It trades at 2.6× enterprise value to sales against a peer median of 5.3× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.5 points above its cost of capital (6.1% WACC).
Credit H. Lundbeck A/S has 2 bonds outstanding ($1.11B), rated BBB- by the agencies and trading like BBB- at a weighted spread of 118 bp.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | DKK 26.2B | DKK 24.4B | DKK 22.1B | DKK 19.9B | DKK 18.2B |
| Revenue growth | — | +10% | +11% | +9% | — |
| Gross profit | DKK 20.4B | DKK 19.4B | DKK 17.2B | DKK 15.3B | DKK 14.2B |
| EBITDA | DKK 9.13B | DKK 8.66B | DKK 6.17B | DKK 5.21B | DKK 4.66B |
| Net income | DKK 4.05B | DKK 3.19B | DKK 3.14B | DKK 2.29B | DKK 1.92B |
| Free cash flow | DKK 4.75B | DKK 4.34B | DKK 2.90B | DKK 3.81B | DKK 2.07B |
| Capital expenditure | DKK 662M | DKK 618M | DKK 565M | DKK 501M | DKK 820M |
| Total debt | DKK 8.66B | DKK 11.7B | DKK 17.0B | DKK 4.39B | DKK 5.76B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| H. Lundbeck A/S HLUN-A.CO | $9.16B | +69% | +9% | 26% | 2.6× | -6.6% |
| Otsuka Hldgs 4578.T | $39.9B | +9% | +11% | 18% | 2.3× | 1.6% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 3.6× | 10.5% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HLUN-A.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +30.6% | +4.2% | 2nd highest of 21 |
| 6-month return | +69.2% | +19.2% | 3rd highest of 21 |
| Distance from 52-week high | -2.6% | -11.2% | 3rd highest of 21 |
| Revenue growth (TTM) | +9.1% | +15.3% | 6th lowest of 20 |
| Operating margin | 25.5% | 15.4% | 3rd highest of 19 |
| EV / Sales | 2.6× | 5.3× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -6.6% | 17.3% | 3rd least demanding of 15 |
| Growth delivered (Del g) | +6.6% | +9.7% | 2nd lowest of 15 |
| Hurdle (Req g minus delivered) | -13.2 pp | +3.7 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +9.5 pp | +1.4 pp | 5th highest of 19 |
| EV / EBITDA | 7.4× | 23.1× | 3rd cheapest of 14 |
| Net debt / EBITDA | 0.6× | -0.7× | 6th most indebted of 14 |
| Bond spread | 118 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | 2.6× | -6.6% | +6.6% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 6.0× | n/a | n/a |
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |
| Pharmaron Beijing 3759.HK | Hong Kong | $9.65B | +48% | +24% | 14% | 4.4× | n/a | n/a |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 2.1× | -4.7% | +9.3% |
| TG Therapeutics TGTX | United States | $9.99B | +66% | +69% | 21% | 11.4× | 43.0% | +426.7% |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 13.6× | 17.5% | +10.0% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.25B | -7% | +9% | 3% | 0.3× | -9.7% | +7.4% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | 29.0× | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 4.7× | 27.3% | +9.4% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 7.4× | 7.3% | +12.6% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | 5.0× | 32.5% | +7.3% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $7.74B | -15% | +10% | 6% | 2.2× | 19.9% | +5.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 3.4× | 17.2% | +8.7% |
| Repligen RGEN | United States | $11.0B | +55% | +14% | 9% | 13.5× | 56.9% | +15.0% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 2.4× | 7.1% | +7.1% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 7.3× | 10.4% | +45.5% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 7.3× | 23.9% | +16.6% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 2.1× | -6.8% | +10.8% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 5.7× | n/a | n/a |
H. Lundbeck A/S has 2 bonds outstanding with $1.11B face value. The agencies rate it BBB-; its bonds trade like BBB-. Weighted yield 4.26%, a spread of 118 bp over government bonds.